(NASDAQ: SPRB) Spruce Biosciences's forecast annual revenue growth rate of 79.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Spruce Biosciences's revenue in 2024 is $10,127,000.On average, 3 Wall Street analysts forecast SPRB's revenue for 2024 to be $188,077,431, with the lowest SPRB revenue forecast at $82,309,598, and the highest SPRB revenue forecast at $279,852,633. On average, 1 Wall Street analysts forecast SPRB's revenue for 2025 to be $214,004,955, with the lowest SPRB revenue forecast at $214,004,955, and the highest SPRB revenue forecast at $214,004,955.
In 2026, SPRB is forecast to generate $2,654,484,536 in revenue, with the lowest revenue forecast at $1,057,678,334 and the highest revenue forecast at $4,251,290,737.